S.Amdt. 2884

SA 2884. Ms. COLLINS submitted an amendment intended to be proposed
by her to the bill S. 4638, to authorize appropriations for fiscal year
2025 for military activities of the Department of Defense, for military
construction, and for defense activities of the Department of Energy,
to prescribe military personnel strengths for such fiscal year, and for
other purposes; which was ordered to lie on the table; as follows:

At the end of subtitle E of title VII, add the following:

SEC. 750. REVIEW ON USE OF MONOCLONAL ANTIBODIES FOR THE
PREVENTION, TREATMENT, OR MITIGATION OF
SYMPTOMS RELATED TO MILD COGNITIVE IMPAIRMENT
OR ALZHEIMER'S DISEASE.

(a) Findings; Sense of Congress.--
(1) Findings.--Congress finds the following:
(A) There are multiple treatments for Alzheimer's disease
that are approved by the Food and Drug Administration and are
shown to reduce the rate of disease progression and to slow
cognitive and functional decline.
(B) Alzheimer's disease is a progressive disease affecting
almost 7,000,000 people in the United States, and approved
treatment options for such disease are most effective when
administered early in the disease course.
(C) Following traditional approval by the Food and Drug
Administration, the Centers for Medicare & Medicaid Services
announced broader coverage of monoclonal antibodies directed
against amyloid for the treatment of Alzheimer's disease and
the Department of Veterans Affairs has also established a
criteria for use of such treatments.
(D) The TRICARE program has a role in facilitating timely
and equitable beneficiary access to novel therapeutics,
including monoclonal antibodies approved by the Food and Drug
Administration for the treatment of Alzheimer's disease.
(2) Sense of congress.--It is the sense of Congress that
Congress encourages continued collaboration between the
Department of Defense, the Centers for Medicare & Medicaid
Services, and other Federal agencies to reduce coverage gaps
and ensure that all people in the United States, including
members of the Armed Forces and their dependents, with
Alzheimer's disease and related dementias have access to
effective treatments.
(b) Review and Report.--Not later than 30 days after the
date of the enactment of this Act, the Secretary of Defense
shall review the policy manual for the TRICARE program
relating to the exclusion of the use of monoclonal antibodies
for the prevention, treatment, or mitigation of symptoms
related to mild cognitive impairment or Alzheimer's disease,
and submit to the Committees on Armed Services of the Senate
and the House of Representatives a report that--
(1) outlines the review process of the Department of
Defense for including or excluding the use of monoclonal
antibodies;
(2) assesses whether the policy of the Department aligns
with current science;
(3) indicates whether the Secretary has or is currently
restricting access by beneficiaries under the TRICARE program
to therapies for the treatment of Alzheimer's disease that
are approved by the Food and Drug Administration; and
(4) indicates whether there are any disparities in
treatment for Alzheimer's disease under the TRICARE program
in different care delivery settings.
(c) TRICARE Program Defined.--In this section, the term
``TRICARE program'' has the meaning given that term in
section 1072 of title 10, United States Code.
______